ITGAM and cancer: In fact, this is supported by our demonstrated association of PG2 treatment with enhanced CD11b expression (Figure 5), especially as CD11b+ TAMs/MDMs display of an anti-cancer phenotype and association with reduced angiogenesis, reversed immune suppression, acquisition of a benign phenotype, repressed invasiveness, and invariably disease remission [30,46,47].